Growing Number of Women Filing Lawsuits Over Depo-Provera's Link to Brain Tumors

DALLAS - EntSun -- As the Depo-Provera meningioma multidistrict litigation (MDL 3140) continues to grow in the Northern District of Texas, a new legal resource has launched to help affected women understand their rights and evaluate potential claims.

DepoProveraClaims.com provides free educational information about the connection between Depo-Provera (medroxyprogesterone acetate) injections and the development of meningioma, a type of brain tumor. The site offers state-by-state statute of limitations data, eligibility screening tools, and updates on the federal litigation.

The FDA added a boxed warning to Depo-Provera's label in 2024 acknowledging the increased risk of meningioma in patients receiving medroxyprogesterone acetate. Studies have shown that the injectable form delivers significantly higher concentrations of the hormone compared to oral formulations, which researchers believe explains the elevated risk.

"Many women who received Depo-Provera injections over months or years are only now learning about the potential link to brain tumors," said the Ruja Media editorial team. "Our goal is to provide clear, accurate information so they can make informed decisions about pursuing legal claims before filing deadlines pass."

More on EntSun News

• Dayton Fashion Week™ and Fashion Week of Cincinnati™ Open Designer Invitation Requests for 2027
• Fashion Sourcing I Leading B2B Marketplace For Custom Apparel Manufacturer in China
• DJ Drewstyle Announces March 2026 Performance Schedule at Estelle Scottsdale
• Detroit Hip-hop Takes Center Stage: Historic Official Sxsw Showcase Spotlights The City's Rising Music Economy
• Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services

MDL 3140 was established in 2024 with bellwether trial dates set for December 2026. The litigation involves allegations that Pfizer (which acquired Pharmacia & Upjohn, the original manufacturer) failed to adequately warn patients and healthcare providers about the meningioma risk despite decades of available research.

Resources Available:

State-by-state filing deadlines: https://depoproveraclaims.com/states/

Free eligibility screening: https://depoproveraclaims.com/do-i-qualify/

MDL updates: https://depoproveraclaims.com/blog/

FAQ: https://depoproveraclaims.com/faq/As the Depo-Provera meningioma

About Ruja Media

Ruja Media provides legal information resources connecting individuals affected by pharmaceutical and environmental litigation with qualified legal representation. The organization is not a law firm.